{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:11:48Z","timestamp":1781788308917,"version":"3.54.5"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1584,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1177\/0091270010372387","type":"journal-article","created":{"date-parts":[[2010,9,24]],"date-time":"2010-09-24T02:42:43Z","timestamp":1285296163000},"page":"695-705","source":"Crossref","is-referenced-by-count":49,"title":["Safety, Tolerability, and Pharmacokinetics of Eliglustat Tartrate (Genz-112638) After Single Doses, Multiple Doses, and Food in Healthy Volunteers"],"prefix":"10.1002","volume":"51","author":[{"given":"M. Judith","family":"Peterschmitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Blankstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina","family":"Puga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Bonate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"10.1177\/0091270010372387-BIB1|cit1","first-page":"3635","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Beutler","year":"2001"},{"key":"10.1177\/0091270010372387-BIB2|cit2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am J Med"},{"key":"10.1177\/0091270010372387-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1177\/0091270010372387-BIB4|cit4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"10.1177\/0091270010372387-BIB5|cit5","volume-title":"Miglustat [package insert]","year":"2008"},{"key":"10.1177\/0091270010372387-BIB6|cit6","doi-asserted-by":"crossref","first-page":"27108","DOI":"10.1016\/S0021-9258(18)47132-3","article-title":"N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing","volume":"269","author":"Platt","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1177\/0091270010372387-BIB7|cit7","doi-asserted-by":"crossref","first-page":"14662","DOI":"10.1074\/jbc.274.21.14662","article-title":"Improved inhibitors of glucosylceramide synthase","volume":"274","author":"Lee","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1177\/0091270010372387-BIB8|cit8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0009-3084(80)90057-2","article-title":"Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain","volume":"26","author":"Vunnam","year":"1980","journal-title":"Chem Phys Lipids"},{"key":"10.1177\/0091270010372387-BIB9|cit9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"McEachern","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1177\/0091270010372387-BIB10|cit10","volume-title":"Food-Effect Bioavailability and Fed Bioequivalence Studies","author":"US Food and Drug Administration (FDA)","year":"2002"},{"key":"10.1177\/0091270010372387-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/009286159502900324","article-title":"Assessment of dose proportionality: report from the Statisticians in the Pharmaceutical Industry PK UK Joint Working Party","volume":"29","author":"Gough","year":"1995","journal-title":"Drug Inf J"},{"key":"10.1177\/0091270010372387-BIB12|cit12","doi-asserted-by":"crossref","first-page":"E609","DOI":"10.1208\/aapsj070363","article-title":"Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT\/QTc prolongation","volume":"7","author":"Piotrovsky","year":"2005","journal-title":"AAPS J"},{"key":"10.1177\/0091270010372387-BIB13|cit13","volume-title":"The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Preliminary concept paper draft 4","author":"US Food and Drug Administration (FDA)","year":"2004"},{"key":"10.1177\/0091270010372387-BIB14|cit14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A Phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270010372387","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1177\/0091270010372387\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:57:23Z","timestamp":1657803443000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1177\/0091270010372387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"URL":"https:\/\/doi.org\/10.1177\/0091270010372387","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}